Compare F5 Inc (FFIV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Neurocrine Biosciences Inc — how do they compare? F5 Inc trades at $475.94 (market cap $26.14B), while Neurocrine Biosciences Inc trades at $142.68 (market cap $14.36B). The key difference: F5 Inc is the larger of the two by market cap, and F5 Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FFIV | NBIX | |
|---|---|---|
Market Cap | $26.14B | $14.36B |
Volume | 503,146 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $469.79 | $185.50 |
52-Week Low | $223.99 | $123.10 |
Typical Hold Time | 38 Days | 23 Days |
Enterprise Value | $24.78B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FFIV trades at $467.57, up 0.2% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.73 beating expectations of $4.00. Revenue grew to $3.09B in 2025, and net income margin improved to 21.95%. Recent news highlights F5's leadership in WAAP platforms and AI security partnerships, reinforcing its market position.
The outlook remains positive given earnings momentum and strategic initiatives in AI security, though valuation multiples like P/E of 36.78 suggest premium pricing. Risks include competitive pressures and execution challenges in integrating new technologies. Analyst consensus is mixed with a $416.60 price target below current levels, indicating caution despite growth prospects.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
